Matthew Pratt Whalen
Director · Telomir Pharmaceuticals, Inc.
Individual
- 2024
- Jul 27, 2026
- 4
Other insiders active in the same sector
No other insider has filed at Matthew Pratt Whalen's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- John Oyler - $189.61M in ONC purchases and sales in the last 12 months
- BVF PARTNERS L P - $173.67M in KYMR purchases and sales in the last 12 months
- BAKER BROS. ADVISORS LP - $172.50M in KYMR purchases and sales in the last 12 months
- Keith S. Manchester - $154.47M in ROIV purchases and sales in the last 12 months
- QVT Financial LP - $147.38M in ROIV purchases and sales in the last 12 months
- Daniel Allen Gold - $147.38M in ROIV purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Matthew Pratt Whalen?
Matthew Pratt Whalen is a corporate insider, tracked as Director of Telomir Pharmaceuticals, Inc. (TELO). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Matthew Pratt Whalen submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
